Are Analysts Bullish about Johnson & Johnson (NYSE:JNJ) after last week?

Johnson & Johnson (NYSE:JNJ) Logo
Investors sentiment decreased to 0.84 in Q1 2019. Its down 0.02, from 0.86 in 2018Q4. It dived, as 57 investors sold Johnson & Johnson shares while 837 reduced holdings. 129 funds opened positions while 620 raised stakes. 1.84 billion shares or 2.89% more from 1.79 billion shares in 2018Q4 were reported.
Cambridge Advisors Inc has invested 1.03% in Johnson & Johnson (NYSE:JNJ). Amg National Comml Bank has 3,030 shares for 0.03% of their portfolio. Viking Fund Management Limited Liability Co reported 34,000 shares. Pennsylvania-based Fulton Bankshares Na has invested 0.61% in Johnson & Johnson (NYSE:JNJ). Thomas White International Limited holds 6,218 shares. Litman Gregory Asset has 0.02% invested in Johnson & Johnson (NYSE:JNJ) for 426 shares. Hourglass Cap Ltd Limited Liability Company invested 0.82% in Johnson & Johnson (NYSE:JNJ). 853,664 are held by State Treasurer State Of Michigan. Long Road Counsel Llc reported 1.54% of its portfolio in Johnson & Johnson (NYSE:JNJ). Coldstream Management owns 0.63% invested in Johnson & Johnson (NYSE:JNJ) for 51,286 shares. 8,832 are held by Quantum Cap Management. Arrowmark Colorado Limited Liability Corp has 8,360 shares for 0.01% of their portfolio. Everence Capital Management Inc owns 65,181 shares for 1.59% of their portfolio. Page Arthur B owns 35,247 shares or 4.11% of their US portfolio. Spirit Of America Management Ny reported 0.18% in Johnson & Johnson (NYSE:JNJ).

Since June 11, 2019, it had 1 insider purchase, and 0 selling transactions for $419,040 activity.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 5 analysts covering Johnson & Johnson (NYSE:JNJ), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Johnson & Johnson has $157 highest and $140 lowest target. $148.80’s average target is 13.44% above currents $131.17 stock price. Johnson & Johnson had 13 analyst reports since March 15, 2019 according to SRatingsIntel. Morgan Stanley maintained the shares of JNJ in report on Tuesday, August 27 with “Equal-Weight” rating. The stock has “Outperform” rating by Credit Suisse on Thursday, May 16. The firm has “Hold” rating given on Friday, June 21 by Barclays Capital. The stock of Johnson & Johnson (NYSE:JNJ) earned “Outperform” rating by Credit Suisse on Wednesday, April 17. Raymond James maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, July 17. Raymond James has “Outperform” rating and $14600 target. BMO Capital Markets maintained the shares of JNJ in report on Wednesday, April 17 with “Outperform” rating. The firm earned “Equal-Weight” rating on Wednesday, April 17 by Morgan Stanley. Raymond James maintained Johnson & Johnson (NYSE:JNJ) on Monday, March 25 with “Buy” rating. The firm earned “Outperform” rating on Wednesday, April 17 by Raymond James. Below is a list of Johnson & Johnson (NYSE:JNJ) latest ratings and price target changes.

27/08/2019 Broker: Morgan Stanley Rating: Equal-Weight New Target: $145.0000 Maintain
17/07/2019 Broker: Raymond James Rating: Outperform Old Target: $147.0000 New Target: $146.0000 Maintain
12/07/2019 Broker: Credit Suisse Rating: Outperform New Target: $156.0000 Initiates Coverage On
21/06/2019 Broker: Barclays Capital Rating: Hold New Target: $140 Initiate
16/05/2019 Broker: Credit Suisse Rating: Outperform Old Target: $152.0000 New Target: $156.0000 Maintain
03/05/2019 Broker: BidaskScore Rating: Buy Upgrade
17/04/2019 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $154 New Target: $157 Maintain
17/04/2019 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $151 New Target: $152 Maintain
17/04/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $134 New Target: $145 Maintain
17/04/2019 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $145 New Target: $147 Maintain

The stock increased 1.25% or $1.62 during the last trading session, reaching $131.17. About 5.89M shares traded. Johnson & Johnson (NYSE:JNJ) has declined 1.48% since September 11, 2018 and is downtrending. It has underperformed by 1.48% the S&P500.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $346.58 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 21.79 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “Better Buy: AbbVie vs. Johnson & Johnson – The Motley Fool” on August 25, 2019, also Investorplace.com with their article: “It’s Time to Short Johnson & Johnson Stock – Investorplace.com” published on August 30, 2019, Seekingalpha.com published: “J&J gains after opioid ruling – Seeking Alpha” on August 26, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Finance.Yahoo.com and their article: “How Will Johnson & Johnson’s Opioid Case Ruling Impact Big Pharma Stocks? – Yahoo Finance” published on September 05, 2019 as well as Finance.Yahoo.com‘s news article titled: “What Kind Of Shareholders Own Johnson & Johnson (NYSE:JNJ)? – Yahoo Finance” with publication date: August 13, 2019.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.